Ekso Bionics Q3 revenue up 9.2% to $3.3M; net loss widens to $4.3M; record 33 EksoNR bookings

EKSO BIONICS HOLDINGS, INC.

2022-Q3 EPS reported -$0.92 revenue$9,361,000

Revenue $3.3M (+9.2% YoY); nine-month revenue $9.4M (+30.6% YoY).
Record bookings of 33 EksoNR units in Q3; driven by increase in international orders.
Gross margin fell to 51% in Q3 from 59% a year ago due to higher service and supply chain costs.
Net loss applicable to common stockholders $4.3M ($0.33 per share) vs $2.0M ($0.15) in Q3 2021.
Cash position $29.2M at Sept 30, 2022, down from $40.4M at Dec 31, 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EKSO BIONICS HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $3.3 million, net income $4.3 million, EPS $0.33 per basic and diluted share.

Period: third quarter ended September 30, 2022
Revenue: $3.3 million
Net income: $4.3 million
EPS: $0.33 per basic and diluted share
Result: reported results

Exact text from the filing

results for the three months ended September 30, 2022. Recent Highlights and Accomplishments • Record of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EKSO BIONICS HOLDINGS, INC. reported nine months ended September 30, 2022 results: revenue $9.4 million, net income $11.9 million, EPS $0.92 per basic and diluted share.

Period: nine months ended September 30, 2022
Revenue: $9.4 million
Net income: $11.9 million
EPS: $0.92 per basic and diluted share
Result: reported results

Exact text from the filing

of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong cash position of $29.2 million as of September 30, 2022 “Our third quarter results reflected

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001549084-22-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.